Welcome to our dedicated page for Oncotelic Therapeutics SEC filings (Ticker: OTLC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Oncotelic Therapeutics, Inc. filings document formal disclosures for a clinical-stage biopharmaceutical issuer with oncology, rare-disease, AI-enabled research and drug-delivery assets. Recent Form 8-K reports cover material definitive agreements, including the TechForce Robotics joint development and licensing framework for AI-enabled GMP robotic systems using the PDAOAI platform, the completed Lunai Bioworks asset transaction involving nose-to-brain delivery patents, and financing arrangements tied to convertible debt and warrants.
OTLC filings also describe capital-structure and governance matters, including a performance-based restricted stock agreement involving Series A Preferred Stock, common-stock conversion terms, secured-note collateral and warrant issuances. Other filings include annual-results exhibits, late annual-report notices on Form 12b-25, and furnished updates on GMP Bio interests, Sapu Nano's Deciparticle nanomedicine platform, everolimus toxicology data and pipeline disclosures.
Oncotelic Therapeutics, Inc. has filed a Form S-1 covering the resale of 309,717,647 shares of common stock by Mast Hill Fund, LP. The shares include up to 294,117,647 shares issuable under an Equity Purchase Agreement, 10,000,000 shares from conversion of debt under a Note Purchase Agreement and related warrants, plus 2,250,000 commitment fee shares and customary anti-dilution adjustments.
The company will not receive any proceeds from Mast Hill’s resale of these shares, but will receive cash when it issues shares to Mast Hill under put notices in the Equity Purchase Agreement. As of November 17, 2025, the shares that may be sold would represent about 39.1% of the company’s common stock, assuming full issuance, conversion and warrant exercise under these arrangements.
Oncotelic is a clinical-stage biopharma company focused on orphan oncology and other indications through its own pipeline and a joint venture, with its principal asset a minority interest in GMP Bio. The company has no product revenue, reported an accumulated deficit of about $39.1 million and a net loss attributable to Oncotelic of about $1.1 million for the nine months ended September 30, 2025, and its auditors express substantial doubt about its ability to continue as a going concern.
Oncotelic Therapeutics, Inc. (OTLC) disclosed an insider equity award for Chairman and CEO Vuong Trieu, who is also a director and 10% owner. A Form 4 reports that he received 4,065 shares of Series A Convertible Preferred Stock on 11/17/2025, classified as an acquisition. Each preferred share is convertible at the holder’s option into common stock on a one-for-one thousand basis, representing 4,065,000 underlying common shares. The preferred shares were issued to Dr. Trieu as compensation tied to performance milestones under a Restricted Stock Agreement dated November 17, 2025, and are held directly.
Oncotelic Therapeutics, Inc. reported no revenue for the three and nine months ended September 30, 2025 and continued to operate at a loss. Net loss attributable to the company was $1.05 million for the quarter, improving from $3.30 million a year earlier, and $1.07 million for the nine‑month period versus $3.92 million in 2024. Operating expenses fell sharply year over year due to the absence of a prior $3.2 million goodwill impairment.
Cash and restricted cash totaled $429,000 at September 30, 2025, while current liabilities were $20.1 million, including $10.3 million of convertible and short‑term debt and $3.5 million of related‑party debt. Management discloses a substantial doubt about the company’s ability to continue as a going concern, citing cumulative losses of about $39.1 million, negative working capital of roughly $18.5 million, and negative operating cash flow. The company is relying on convertible notes, short‑term related‑party loans, and equity purchase agreements with Peak One and Mast Hill, while its 45% stake in JV partner GMP Bio is carried at $22.65 million based on a Level 3 fair value election.
Oncotelic Therapeutics, Inc. filed a Form 12b-25, notifying a late Form 10-Q for the quarter ended September 30, 2025.
The company says it was unable to compile the necessary financial information to complete the filing without unreasonable effort or expense and expects to file within the permitted extension period. The notification lists Amit Shah, Chief Financial Officer, as the signatory and contact.
Oncotelic Therapeutics (OTLC) furnished an investor presentation given by CEO Dr. Vuong Trieu at LD Micro in San Diego on October 21, 2025. The presentation, filed as Exhibit 99.1, includes forward-looking statements covering areas such as JV plans (including a potential IPO), clinical development timing and data reporting, regulatory approvals, the company’s nanoparticle platform, a planned DAO-based company, pet and animal health initiatives, and token-related registrations and tradability.
The materials are furnished under Item 8.01 and are not deemed “filed,” which limits their incorporation into other SEC filings.